Image
Point-of-Care™ 101

Choosing Your Path in Systemic Lupus Erythematosus

From Patient Evaluations to New Targeted Therapies

Classification Criteria

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.

Disease Management Guidelines

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.

Patient Resources

American College of Rheumatology

Lupus Foundation of America

Lupus Research Alliance

Suggested Readings

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Choi MY, et al. Ann Rheum Dis. 2022. [E-pub ahead of print.]

Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus.

Choi MY, et al. Arthritis Rheumatol. 2022;74(2):274-283.

Update οn the diagnosis and management of systemic lupus erythematosus.

Fanouriakis A, et al. Ann Rheum Dis. 2021;80(1):14-25.

Two-year, randomized, controlled trial of belimumab in lupus nephritis.

Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.

Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries.

Izmirly PM, et al. Arthritis Rheumatol. 2021;73(6):991-996.

All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Moghaddam B, et al. Rheumatology. 2021;61(1):367-376.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Rovin BH, et al. Lancet. 2021;397(10289):2070-2080.

SLE mortality remains disproportionately high, despite improvements over the last decade.

Singh RR, Yen EY. Lupus. 2018;27(10):1577-1581.

Activity
Evaluating the Patient with SLE

Module 1

Activity
Targeted Treatment Options for SLE

Module 3

Activity
Real-World Strategies for Managing Moderate-to-Severe SLE

Module 2

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Cause for Alarm

New Avenues to the Management of Severe Asthma

Maybe It’s NOT Mechanical Back Pain

Getting on the Fast Track to Identify AxSpA

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps